HENDERSON, NV, United States, via ETELIGIS INC., 11/12/2014 – – Made available on the NHS Tariff in 2012, Pro-Sil was introduced to the UK by Amred Healthcare (Biodermis UK affiliate) as a response to a gap in the availability of quality, medical-grade silicone scar treatment options. The product has proven itself since, by clinching back-to-back wins as “Best Home Use Device” at London’s prestigious MyFaceMyBody Awards. As a result of continued efforts by Amred Healthcare, Pro-Sil will soon be available at 290 Lloyds Pharmacy locations.
“This is a great victory for Pro-Sil, and for UK scar treatment candidates. This relationship will allow us to leverage the reach of the Lloyds Pharmaceutical network to provide further exposure for Pro-Sil, and continued results for patients.”
— Jeff Schleuning, Ph.D. EVP, Partner, Biodermis
Introduced in 2006 as a convenient, easy-to-use, glide-on alternative to ointments, Pro-Sil® elevated silicone scar treatment products to a new level. The patented Pro-Sil stick was designed to store compactly and worry-free in a purse or pocket, without the drips or leaks associated with silicone ointments. In the U.K., Pro-Sil is distributed by Amred Healthcare (amredhealthcare.com). Amred Healthcare can be reached online or by phone at 033-0333-0079.
“We extend our sincerest gratitude to Lloyds Pharmacy, and look forward to working with the Lloyds team to gain exposure for Pro-Sil, and make this fantastic scar treatment available to more UK citizens who need it.”
— Steve Donnelly, Managing Director, Amred Healthcare, LTD
Biodermis has led the industry with innovative, patented silicone scar treatment products for over 25 years. They are focused on providing the highest quality, most effective scar management and skincare products available. Biodermis strives to be a resource of valuable information to physicians, patients, moms, dads and kids worldwide.
CONTACT:
Media Inquiries
Sean Mahoney, Mahoney Advertising
(702) 260-4466
sean
Biodermis
1820 Whitney Mesa Drive
Henderson, NV 89014
800.322.3729
SOURCE: Biodermis
Leave a Reply